Helyx Industries S.p.A. Stock Price

Helyx Industries S.p.A., a healthcare biotech company, develops, produces, and markets invitro diagnostic medical devices in Italy. The company through its Sagitta, a proprietary reagent platform designed to support deep multiplexing qPCR; and stable multiplex reagents. It also offers HYRIS bAPP, a software interface for managing and instructing Hyris system operations, as well as HYRIS bCUBE, an IVDR device compliant, designed according to industrial quality and operational safety criteria; and HYRIS bGATE, a gateway device that allows laboratories to integrate data and results. In addition, the company’s platforms also comprise Hyris System, a proprietary technology, offers revolutionary solutions to laboratories and healthcare professionals, enabling the decentralization of genetics, as well as offers agrifood and nutraceuticals catalogue, and development and OEM services. Further, it develops customized NGS panels, advanced sequencing solutions and optimized bioinformatics pipelines to support clinical and research applications; and provides various tests and reagents for sexually transmitted diseases and HPV. The company was formerly known as Ulisse Biomed S.p.A. and change its name to Helyx Industries S.p.A. in December 2025. Helyx Industries S.p.A. was founded in 2015 and is based in Udine, Italy.